The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor.

The present invention provides novel benzazepine compounds of Formula (1), or salts thereof, having vasopressin V.sub.1a and V.sub.2 antagonisms, and medical uses thereof. ##STR00001##
In the formula, R.sup.1 is optionally substituted C.sub.1-6 alkyl, etc.; L is —C(═O)—NH—, etc.; Ring A.sup.1 is a hydrocarbon ring, etc.; Ring A.sup.2 is a hydrocarbon ring, etc.; and each of Rings A.sup.1 and A.sup.2 may have at least one substituent.

The present invention provides novel benzazepine compounds of Formula (1), or salts thereof, having vasopressin V.sub.1a and V.sub.2 antagonisms, and medical uses thereof. ##STR00001##
In the formula, R.sup.1 is optionally substituted C.sub.1-6 alkyl, etc.; L is —C(═O)—NH—, etc.; Ring A.sup.1 is a hydrocarbon ring, etc.; Ring A.sup.2 is a hydrocarbon ring, etc.; and each of Rings A.sup.1 and A.sup.2 may have at least one substituent.

The present invention relates to a new type of eutectic crystal of lorcaserin hydrochloride and benzoic acid. Compared with the prior art, the eutectic crystal has the improved properties of good stability, low solubility, and being suitable for the application of controlled-release preparation. The present invention also relates to a method for preparing the eutectic crystal, a pharmaceutical composition thereof and the use thereof in the manufacture of drugs for treating and/or preventing diseases associated with 5HT.sub.2C.

The present invention relates to a new type of eutectic crystal of lorcaserin hydrochloride and benzoic acid. Compared with the prior art, the eutectic crystal has the improved properties of good stability, low solubility, and being suitable for the application of controlled-release preparation. The present invention also relates to a method for preparing the eutectic crystal, a pharmaceutical composition thereof and the use thereof in the manufacture of drugs for treating and/or preventing diseases associated with 5HT.sub.2C.

The present invention relates to derivatives of formula (I)

##STR00001##

wherein (R.sup.1).sub.n, ring (A), Y.sup.1, Y.sup.2, X, R.sup.4, L.sup.1, L.sup.2, and A.sup.1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.

The present invention relates to compounds of formula (I):

##STR00001##

and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

The present invention relates to compounds of formula (I):

##STR00001##

and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

This invention relates to novel benzazepine sulfonamide compounds of the formula

##STR00001## wherein R.sup.4 or R.sup.5 is —SO.sub.2—NR.sup.7R.sup.8 and R.sup.1 to R.sup.8 and Y are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.

This invention relates to novel benzazepine sulfonamide compounds of the formula

##STR00001## wherein R.sup.4 or R.sup.5 is —SO.sub.2—NR.sup.7R.sup.8 and R.sup.1 to R.sup.8 and Y are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.